US Patent Issued to Icahn School of Medicine at Mount Sinai on Nov. 11 for "Heterobifunctional compounds as degraders of HPK1" (New York Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,465,648, issued on Nov. 11, was assigned to Icahn School of Medicine at Mount Sinai (New York).

"Heterobifunctional compounds as degraders of HPK1" was invented by Jian Jin (New York), Steven Burakoff (New York), H. Umit Kaniskan (New York), Sansana Sawasdikosol (New York), He Chen (New York), Joshua Brody (New York) and Nina Bhardwaj (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation/disruption compounds including a HPK1 ligand, a degradation/disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated diseases."

The patent was filed on May...